Skip to main content

CLEPIC

CLEPIC LogoSave the Date for 

Clinical Epigenetics International Conference - CLEPIC 2023
Szczecin, Poland, May 24 – 26, 2023
 

More information at  https://www.clepic.org/



Welcoming words from Lucia Altucci and Marianne Rots, Editors in Chief of Clinical Epigenetics:


The need to meet and greet

Scientists need to meet to stay up-to-date within and beyond one’s own research field, to exchange and fuel new ideas, to keep inspired and to inspire others. Corona-volente, we aim to offer you such platform by bringing together the editors, authors and readers of Clinical Epigenetics as well as the newly launched Epigenetics Communications. Moreover, we will invite industrial partners and public bodies, with a focus on training the next generation of multidisciplinary multi-epiomics scientists. This conference starts a series of annual conferences devoted to fully exploiting the many applications of epigenetics in health and disease as well as in all kingdoms of life (biotech, crop breeding, etc.).

Looking forward to meeting and greeting many of you in a relaxed atmosphere full of state-of-the-art epigenetics!

EACR Cellular Bases for Patient Response to Cancer Therapies

New Content Item


We are proud to share information about the upcoming meeting:
EACR Cellular Bases for Patient Response to Cancer Therapies
Date & Location: 14 - 16 November 2023 | Lyon, France


This conference will focus on the most recent studies that have uncovered novel molecular pathways involved in response anticancer therapy. A panel of speakers involved in cutting-edge studies on the biological and cellular bases for therapeutic response in cancer will share their vision on how these disruptive discoveries could be exploited to rethink cancer therapies to ultimately improve therapeutics. https://www.eacr.org/conference/cellularbases2023/index


Check out Confirmed Speakers here.


Key dates:
Travel grant application deadline: 19 September 2023
Abstract submission deadline: 19 September 2023
Early registration deadline: 17 October 2023

EACR-AstraZeneca Cancer Epigenetics

New Content Item


We are proud to share information about the upcoming meeting:
EACR-AstraZeneca Cancer Epigenetics


Date & Location: 05 – 06 December 2023 | Virtual Event, Worldwide


Epigenetic control is essential for development and differentiation, and this control mechanism is very frequently deregulated in cancer. Several small molecule inhibitors have been developed in recent years that have either been approved for clinical use or are in preclinical and clinical trials. This conference will focus on basic and clinical aspects of targeting a broad panel of epigenetic proteins in cancer, either as monotherapies, or as combination therapies, including the use of immune checkpoint inhibitors to increase drug sensitivity and overcome chemoresistance.


Check out Confirmed Speakers here.


Key dates:
Abstract submission deadline: 09 October 2023

Registration deadline: 13 November 2023

Call for Papers: Alternative Medicine and Epigenetics

New Content ItemWe are proud to announce our new cross-journal thematic series, guest edited by Andy T. Y. Lau and Amy Yan-Ming Xu entitled: “Alternative Medicine and Epigenetics” to be published in Clinical Epigenetics and Epigenetics Communications. Alternative medicine has gained increasing attention over the past decades. These alternative medicinal approaches not only are effective in relieving disease complications and even in healing of diseases, but are also beneficial for disease prevention. Interestingly, various studies have demonstrated epigenetic effects exert by some subcategories of alternative medicine. In this thematic series, we welcome research and review articles that focus on the complex realm between alternative medicine and epigenetic regulation. Find out more about the scope here.

New thematic series: Multiscale chromatin dynamics

New Content ItemWe are proud to announce a new cross-journal thematic series between Clinical Epigenetics and Epigenetics Communications, guest edited by Wim Vanden Berghe and Pernette Verschure. The last few years have seen a wealth of knowledge on the role of epigenetic gene regulation in (patho-)physiological processes. New insights relate to the highly dynamic nature of epigenetic systems. Epigenetic regulatory proteins are in constant motion in the nucleus, exchanging between chromatin-bound and unbound states. In addition,  various layers of chromatin folding show defined dynamics. The causal relationship between these dynamics of chromatin and nuclear organization with gene activity and silencing is still an open question of great importance. Find out more about the scope here.

New thematic series: Epigenetic Biomarkers

New Content ItemWe are proud to announce a new thematic series, guest edited by Dawn DeMeo, James Flanagan, Harold Snieder, and Tomasz K. Wojdacz. We discuss current progress in development of epigenetic biomarkers for clinical use in common complex diseases of aging and welcome both original research and reviews. The sections of the collection include types of epigenetic biomarkers and readiness for IVD use, progress towards clinical use of biomarkers, single versus multiple biomarkers and risk scores, major stages of clinical validation of the biomarker, biomarker detection technologies suitable for IVD use and significance of bioinformatics, and ethics and regulatory aspects of IVD epigenetic biomarkers. Find out more about the scope here.

Announcing the launch of "Epigenetics Communications"!

New Content ItemWe are pleased to announce the launch of a companion journal to Clinical Epigenetics: Epigenetics Communications! Encompassing the broad spectrum of epigenetics research from basic research to innovations towards therapeutic treatments, Epigenetics Communications is an innovative new, open-access journal devoted to the study of epigenetic principles and mechanisms in basic research settings (without requiring a clinical application). This journal will support the publication of manuscripts that contribute to a further understanding of epigenetic mechanisms that impact functioning of systems and organisms. It will also act as a forum to showcase and discuss alternative conclusions/interpretations of well-established epigenetic phenomena based on (re-)analyses of published or new data. As such, we welcome 'systematic studies', be it positive (expected) or negative (non-expected) with respect to its outcome. Find out more here.

Articles

  1. Authors: Jihoon E. Joo, Khalid Mahmood, Romy Walker, Peter Georgeson, Ida Candiloro, Mark Clendenning, Julia Como, Sharelle Joseland, Susan Preston, Lise Graversen, Mathilda Wilding, Michael Field, Michelle Lemon, Janette Wakeling, Helen Marfan, Rachel Susman…

2022
Cross-journal collection
Alternative Medicine and Epigenetics
Edited by Andy T. Y. Lau and Amy Yan-Ming Xu

Communications in Epigenetics: state of the art and beyond in chromatin biology and pathophysiology
Edited by Renata Z. Jurkowska, Frank Johannes and Tomasz K. Wojdacz

Multiscale chromatin dynamics
Edited by Pernette Verschure and Wim Vanden Berghe

Epigenetic Biomarkers
First published: 4 May 2021
Edited by: Dawn DeMeo, James Flanagan, Harold Snieder, and Tomasz K. Wojdacz

Regenerative Medicine and Epigenetics
First published: 19 January 2021
Edited by: Adele Murrell and Peter Rugg-Gunn

Clinical Epigenetics of COVID-19
First published: 5 August 2020
Edited by: Georges Herbein

2019
Pollution and Epigenetics
First published: 21 January 2019
Edited by: Steven Gray and Wim Vanden Berghe

2018
Cross-journal collection
Pluripotent Stem Cells
First published: 19 July 2018

Cross-journal collection
Asthma Genetics and Epigenetics
Collection first published: 19 October 2016

Epigenetic Drugs
Edited by: Lucia Altucci & Marianne Rots
First published: 23 May 2016

2015
Breakthroughs in clinical epigenetics
Edited by: Marianne Rots
First published: 1 March 2015



Graphical Abstracts Now Available

Authors submitting to Clinical Epigenetics now have the option to include a Graphical Abstract when they submit their manuscript.  An image may be uploaded during submission which, together with the article title and abstract text, should provide the reader with a visual description of the topic covered in the article. Graphical abstracts will appear in the HTML version of the article (but not in the PDF version). Instructions for including graphical abstracts is available in the Submission Guidelines for the appropriate article types.

Editors-in-Chief

Lucia AltucciUniversità degli Studi della Campania, Italy
Marianne RotsUniversity Medical Center Groningen, Netherlands  

Aims & Scope

Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:

  • Aging and development epigenetics
  • Allergy, immunology, and pathogen epigenetics
  • Cancer epigenetics and diagnostics
  • Cardiovascular epigenetics
  • Endocrinology and metabolic epigenetics
  • Environmental epigenetics
  • Epigenetic biomarkers
  • Epigenetic technologies
  • Epigenetic Drugs, Trials and Therapy
  • Innovative therapies
  • Lifestyle epigenetics
  • Neurology and psychiatry epigenetics
  • Regenerative medicine
  • Reproductive and transgenerational epigenetics

For more information on the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here.

Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications

Manuscripts focusing on differential RNA expression levels (coding or non-coding) or on RNA modifications cannot be considered for publication in Clinical Epigenetics since these aspects are not part of epigenetics per se.

In general, non-coding RNAs affect their target genes at the RNA level, which classifies these molecules as post-transcriptional gene expression regulators. The chromatin effects induced by some ncRNA do not yet justify this, to be included as a general mechanism of action of non-coding RNAs. Similarly, although modifications of RNA molecules resemble modifications of DNA or histone proteins, so do post-translational modifications of non-chromatin proteins. As such, RNA modifications are a novel class of markers, but they are not different from general posttranslational protein modifications (which also are not considered part of epigenetics).

For manuscripts on non-coding RNAs or RNA modifications to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
  • insights on the mechanism of action of the non-coding RNA on the chromatin and/or functioning of the DNA; or
  • insights in mitotic stability of the RNA-induced effect.

Editorial Policy Regarding Submissions Focusing on In silico research

Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Clinical Epigenetics, unless the manuscript presents:

  • new insights with well-described strong clinical impact and/or
  • additional insights into biological mechanisms (“wet-lab” validations) and/or
  • validations of findings in a replication cohort.

Archival Content

In October 2011, Clinical Epigenetics became a fully open access journal and is now published as part of BioMed Central's portfolio of journals. To view the journal's content prior to this transition, please see SpringerLink.

Annual Journal Metrics